Alpha Cognition Inc. (ACOG)
| Market Cap | 177.49M +37.4% |
| Revenue (ttm) | 20.20M +171.9% |
| Net Income | -28.12M |
| EPS | -1.30 |
| Shares Out | 21.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 115,596 |
| Open | 8.00 |
| Previous Close | 7.92 |
| Day's Range | 7.82 - 8.21 |
| 52-Week Range | 4.50 - 10.14 |
| Beta | 2.33 |
| Analysts | Buy |
| Price Target | 18.20 (+123.31%) |
| Earnings Date | Nov 11, 2026 |
About ACOG
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The companyâs commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimerâs disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimerâs disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impa... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACOG stock is "Buy." The 12-month stock price target is $18.2, which is an increase of 123.31% from the latest price.
News
Alpha Cognition announces publication of US patent app for Benzgalantamine
Alpha Cognition (ACOG) announced that the United States Patent and Trademark Office, USPTO, published U.S. Patent No. 20260325541-A1, titled âBenzgalantamine for Treating Persistent Post-Concussion Sy...
Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, âACIâ, or the âCompanyâ), a biopharmaceutical company developing and commercializing novel therape...
Alpha Cognition price target raised to $21 from $20 at Raymond James
Raymond James raised the firmâs price target on Alpha Cognition (ACOG) to $21 from $20 and keeps an Outperform rating on the shares. Zunveylâs strong launch continued with 30% sequentialâŠ
Alpha Cognition Earnings Call Transcript: Q3 2026
Q3 revenue rose 30% sequentially to $7.8M as prescription demand and commercial productivity accelerated, with gross margin at 94% and operating spend relatively flat. Management reiterated the 2027 operating profitability target while advancing real-world evidence and payer access efforts.
Alpha Cognition Earnings release: Q3 2026
Alpha Cognition released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
Alpha Cognition Quarterly report: Q3 2026
Alpha Cognition has published its Q3 2026 quarterly earnings report on November 11, 2026.
Alpha Cognition reports Q3 EPS (35c), consensus (33c)
Reports Q3 revenue $7.78M, consensus $9.88M. âThe third quarter was our strongest quarter since the launch of ZUNVEYL, the first new oral Alzheimerâs treatment approved in more than 15 years,ââŠ
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, âACIâ, or the âCompanyâ), a biopharmaceutical company developing and commercial...
Alpha Cognition Slides: Investor presentation
Alpha Cognition has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
Alpha Cognition appoints Caren Deardorf to board of directors
Alpha Cognition (ACOG) announced the appointment of Caren Deardorf to its Board of Directors. Deardorf serves as Chief Business & Strategy Officer at Neutrolis, a private, clinical-stage biotechnology...
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company developing and commercializing novel thera...
Alpha Cognition to Participate in Upcoming Investor Events
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company developing and commercializing n...
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...
Alpha Cognition announces publication of US patent application for ZUNVEYL
Alpha Cognition (ACOG) announced that the United States Patent and Trademark Office, USPTO, published U.S. Patent Application No. 19/090,242, titled âProcess for Preparing Benzgalantamine and Salts Th...
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYLÂź
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing no...
Alpha Cognition to Present New ZUNVEYLÂź (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ or the âCompanyâ), a commercial-stage biopharmaceutical company focused on developing ther...
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (âAlpha Cognitionâ, âACIâ, or the âCompanyâ), a biopharmaceutical company developing novel therapeu...
Alpha Cognition announces CONVERGE RWE on ZUNVEYL
Alpha Cognition (ACOG) announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the...
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYLÂź(Benzgalantamine) Use in Long-Term Care
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongo...
Alpha Cognition management to meet virtually with B. Riley
Virtual Meeting to be held on September 29 hosted by B. Riley.
Alpha Cognition initiated with a Buy at B. Riley
B. Riley analyst William Wood last night initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $21 price target Alpha is a commercial-stage specialty pharma company built aroundâŠ
Alpha Cognition initiated with a Buy at B. Riley
B. Riley initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $21 price target
Alpha Cognition price target raised to $20 from $18 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firmâs price target on Alpha Cognition (ACOG) to $20 from $18 and keeps a Buy rating on the shares. The companyâs âsolidâ salesâŠ
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q2...
Alpha Cognition reports Q2 EPS (40c), consensus (39c)
Reports Q2 revenue $6M, consensus $6.11M. âWe are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,â said Michael McFadden, Chief Executive Officer of Alpha Cognitio...